Innovent
Innovent
Innovent including oncology
Innovent is a leading biotechnology company in China. It aims to produce highly complex and affordable biopharmaceutical products for patients. Since its inception, Innovent has established a product chain of 13 new drugs covering four major disease areas, including oncology, ophthalmology, autoimmune diseases and cardiovascular diseases, and has undertaken 7 National Science and Technology Projects, of which 5 products were selected for the National "Major New Drug Creation" Program and 1 product was selected for the National Key Research and Development Program. Special "Precision Medicine Research".
- All
- News
- Analysis
- Research
Briefing Updated 9 hours ago
· Healthcare
Yuanyin biology completed the pre-A round of financing of more than 100 million yuan
Briefing Updated 4 hours ago
· Healthcare
Aibo biology completed the round C + financing of US $300 million
In depth
Healthcare
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
Briefing Nov 21, 2021 05:59 PM
· Healthcare
Pakistan once again lifted the ban on tiktok
Briefing Nov 19, 2021 02:32 PM
· Healthcare
Yinming biological HPK1 small molecule inhibitor new drug has passed the United States ind, and the dry amd small molecule new drug has completed the phase I clinical trial in the United States
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Nov 19, 2021 09:30 AM
· Healthcare
Tuochuang biology obtained more than 200 million yuan of round B financing to accelerate the development and clinical promotion of innovative antibody drugs
Briefing Nov 18, 2021 09:22 AM
· Healthcare
Lingtai biology completed the pre-A round of financing and is committed to the development of targeted protein degradation drugs
Briefing Nov 17, 2021 10:33 AM
· Healthcare
Tongshu gene has reached strategic cooperation with Ping An health to create a closed loop for accurate diagnosis and treatment of tumors
Briefing Nov 16, 2021 10:33 PM
· Healthcare
Baiji Shenzhou science and technology innovation board IPO registration was approved by the CSRC and plans to raise 20 billion yuan
Briefing Nov 06, 2021 10:00 AM
· Healthcare
Du HaoChen, vice president of AstraZeneca China, is about to join Baiji Shenzhou
Briefing Nov 02, 2021 05:24 PM
· Healthcare
Ouyi biology completed round a + financing
Briefing Nov 02, 2021 05:02 PM
· Healthcare
AI innovative drug R & D enterprise "Yuanyi wisdom ainnocence" won tens of millions of yuan in the first round of financing
Insight
Briefing Oct 20, 2021 09:19 AM
· Healthcare
Kangyuan obtained tens of millions of yuan of round a financing for a long time and accelerated the application of jy108 dual anti drug ind
Briefing Oct 19, 2021 10:21 AM
· Healthcare
Microchip diabetes mellitus new drug glipizide sodium approved in China
Briefing Sep 02, 2021 02:26 PM
· Healthcare
Xinda biology and JinFang medicine have reached global strategic cooperation on KRAS G12C inhibitor gfh925
Briefing Updated 13 hours ago
· Healthcare
2021 Chinese hospital internet influence ranking list released 127 hospitals in 17 provinces and cities
See more
Related Companies
EqualOcean Analysis
- Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- More Room for the Medical Device Market to Grow in China
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.